Why Is Merck Stock Falling Tuesday?

Merck stock falls as the Phase 3 LITESPARK-012 trial for advanced renal cell carcinoma fails to meet primary endpoints. Read the update.

FDA Approves Merck's IDVYNSO For HIV-1 Infection Treatment In Adult Patients

https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026

Federal Court Reportedly Halts Kennedy's Vaccine Panel, Putting COVID, Flu And RSV Shots At Risk

FDA court freeze leaves COVID, flu, RSV vaccines in limbo as Kennedy's ACIP overhaul faces legal challenge.

Merck Announces Results From Phase 3 LITESPARK-012 Trial Evaluating Combination Regimens For First-Line Treatment Of Patients With Advanced Clear Cell Renal Cell Carcinoma

Merck (NYSE:MRK), known as MSD outside of the United States and Canada, and Eisai today announced results from the Phase 3 LITESPARK-012 trial evaluating combination regimens for the first-line treatment of patients with

Merck Announces FDA Priority Review for KEYTRUDA And KEYTRUDA QLEX, Each In Combination With Padcev, For The Treatment Of Patients With Muscle-Invasive Bladder Cancer, With PDUFA Date Set For

If approved, these indications would expand the use of KEYTRUDA and KEYTRUDA QLEX, each in combination with Padcev, as the first perioperative treatments for patients with MIBC regardless of cisplatin eligibility and

7 Health Care Stocks Whale Activity In Today's Session

Merck Says EC Approves ENFLONSIA For Prevention Of Respiratory Syncytial Virus Lower Respiratory Tract Disease In Newborns And Infants

ENFLONSIA is the first and only RSV preventive option in the European Union for administration to infants without the need for weight-based dosingMerck (NYSE:MRK), known as MSD outside of the United States and Canada,

Immutep Gets FDA Boost For Lead Cancer Drug, Stock Doubles

Immutep stock jumps after FDA orphan drug tag for eftilagimod alfa, even as halted Phase 3 trial and mixed analyst views weigh on outlook.

UBS Maintains Buy on Merck & Co, Raises Price Target to $145

UBS analyst Michael Yee maintains Merck & Co (NYSE:MRK) with a Buy and raises the price target from $130 to $145.

Revolution Medicines Rallies After Phase 3 Pancreatic Cancer Trial Doubles Survival Versus Chemo

Revolution Medicines stock rises after Phase 3 daraxonrasib data show survival gains in pancreatic cancer, with regulatory filings planned.

Merk And Daiichi Sankyo JV Receives FDA Priority Review For Ifinatamab Deruxtecan For The Treatment Of Adult Patients With Extensive-Stage Small Cell Lung Cancer

Ifinatamab deruxtecan is a specifically engineered, potential first-in-class B7-H3 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by Daiichi Sankyo and Merck.

Sun Pharma Nears Final Offer For Organon In Largest Overseas Bet

Sun Pharma prepares $12 billion Organon bid after due diligence, advancing financing for its biggest global acquisition push.

Summit Therapeutics Has Scarcity Value In A Crowded Drug Race: Analyst

Stifel initiates coverage on Summit Therapeutics (SMMT) with a Buy rating and $45 price target, citing ivonescimab's $200B market potential.

Merck Lowered Terns Pharmaceuticals Offer Price After Trial Data Review

Merck cuts Terns deal price after TERN-701 data review, while maintaining interest amid competition and CML treatment comparisons.

What's Going On With Merck Stock Tuesday?

Merck begins tender offer for Terns at $53 per share as part of its planned acquisition announced in March 2026.

Merck Commences Cash Tender Offer to Acquire All Outstanding Shares of Terns Pharmaceuticals for $53.00 Per Share

Evaxion Announces Final Patient Visit In One-Year Extension Phase 2 Trial Of Personalized Melanoma Cancer Vaccine EVX-01

EVX-01 is a personalized cancer vaccine currently being evaluated as a treatment for advanced melanoma (skin cancer). In the first two years of the phase 2 trial, patients were treated with EVX-01 in combination with

JP Morgan Maintains Overweight on Merck & Co, Raises Price Target to $135

JP Morgan analyst Chris Schott maintains Merck & Co (NYSE:MRK) with a Overweight and raises the price target from $125 to $135.

Merck Says EU Approves KEYTRUDA, In Combination With Paclitaxel, With Or Without Bevacizumab, For Treatment Of Platinum-Resistant Epithelial Ovarian, Fallopian Tube Or Primary Peritoneal Carc

The KEYTRUDA regimen is the first and only PD-1 inhibitor-based treatment approved in the European Union for these patientsApproval supported by data from the Phase 3 KEYNOTE-B96 trial in which the KEYTRUDA regimen

Tempus AI Stock Jumps, ALERT Trial Results Boost EHR Automation Buzz

Tempus AI says ALERT trial shows higher valve procedures and faster care, while analysts keep a Buy rating with varied price targets.

Merck Locks Infinimmune Alliance To Chase Next-Gen Antibody Drugs

Infinimmune, Merck ink deal to develop human-derived antibodies using the Anthrobody platform. See the full agreement details.

FDA Adverse Event Monitoring System Q4 2025 Flags Multiple Potential New Drug Safety Signals, Including Hypersensitivity, Hypogammaglobulinemia, Colitis, Aplastic Anemia And Rhabdomyolysis Un

https://www.fda.gov/drugs/fda-adverse-event-monitoring-system-aems/october-december-2025-new-safety-information-or-potential-signals-serious-risks-identified-fda

Infinimmune Partners With Merck To Discover And Develop Therapeutic Antibodies Using Human-First AI Platform; Merck Will Have The Exclusive Right To Develop And Commercialize Antibody Candida

Collaboration aims to discover and develop antibodies against multiple therapeutic targets designated by MerckInfinimmune's platform combines large-scale human immune repertoire single cell screening with AI-guided

RBC Capital Reiterates Outperform on Merck & Co, Maintains $142 Price Target

RBC Capital analyst Trung Huynh reiterates Merck & Co (NYSE:MRK) with a Outperform and maintains $142 price target.

Merck Announced Results From Third Positive Phase 3 Comparative Study On Enlicitide Decanoate When Added To Background Statins In Adults With Hypercholesterolemia Who Have A History Of Or Are

Reported Sunday, Merck's Winrevair Demonstrates Statistically Significant 1.02 Wood Units Reduction In PVR In Phase 2 CADENCE Trial, Paving Way For Phase 3 Study

Merck's WINREVAIR met primary endpoint of change in pulmonary vascular resistance (PVR), significantly improving the ability of blood to flow through the lungs to the heartTotality of evidence across hemodynamic,